Leandro C Baia1, Jelmer K Humalda, Marc G Vervloet, Gerjan Navis, Stephan J L Bakker, Martin H de Borst. 1. Department of Internal Medicine, Division of Nephrology, University of Groningen, University Medical Center Groningen, The Netherlands;, †Department of Nephrology, UNIFESP, Sao Paolo, Brazil, ‡Department of Nephrology, VU University Medical Center, Amsterdam, The Netherlands.
Abstract
BACKGROUND AND OBJECTIVES: Circulating fibroblast growth factor 23 (FGF23) is associated with adverse cardiovascular outcomes in CKD. Whether FGF23 predicts cardiovascular mortality after kidney transplantation, independent of measures of mineral metabolism and cardiovascular risk factors, is unknown. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: The association between plasma C-terminal FGF23 and cardiovascular mortality was analyzed in a single-center prospective cohort of 593 stable kidney transplant recipients (mean age ± SD, 52 ± 12 years; 54% male; estimated GFR, 47 ± 16 ml/min per 1.73 m(2)), at a median of 6.1 (interquartile range, 2.7-11.7) years after transplantation. Multivariate Cox regression models were built, adjusting for measures of renal function and mineral metabolism; Framingham risk factors; the left ventricular wall strain markers midregional fragment of pro-A-type natriuretic peptide (MR-proANP) and N-terminal-pro brain natriuretic peptide (NT-proBNP); and copeptin, the stable C-terminal portion of the precursor of vasopressin. RESULTS: In multivariate linear regression analysis, MR-proANP (β=0.20, P<0.001), NT-proBNP (β=0.18, P<0.001), and copeptin (β=0.26, P<0.001) were independently associated with FGF23. During follow-up for 7.0 (interquartile range, 6.2-7.5) years, 128 patients (22%) died, of whom 66 (11%) died due to cardiovascular disease; 54 (9%) had graft failure. FGF23 was associated with an higher risk of cardiovascular mortality in a fully adjusted multivariate Cox regression model (hazard ratio [HR], 1.88 [95% confidence interval (CI), 1.11 to 3.19]; P=0.02). FGF23 was also independently associated with all-cause mortality (full model HR, 1.86 [95% CI, 1.27 to 2.73]; P=0.001). Net reclassification improved for both cardiovascular mortality (HR, 0.07 [95% CI, 0.01 to 0.14]; P<0.05) and all-cause mortality (HR, 0.11 [95% CI, 0.05 to 0.18]; P<0.001). CONCLUSIONS: Plasma FGF23 is independently associated with cardiovascular and all-cause mortality after kidney transplantation. The association remained significant after adjustment for measures of mineral metabolism and cardiovascular risk factors.
BACKGROUND AND OBJECTIVES: Circulating fibroblast growth factor 23 (FGF23) is associated with adverse cardiovascular outcomes in CKD. Whether FGF23 predicts cardiovascular mortality after kidney transplantation, independent of measures of mineral metabolism and cardiovascular risk factors, is unknown. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: The association between plasma C-terminal FGF23 and cardiovascular mortality was analyzed in a single-center prospective cohort of 593 stable kidney transplant recipients (mean age ± SD, 52 ± 12 years; 54% male; estimated GFR, 47 ± 16 ml/min per 1.73 m(2)), at a median of 6.1 (interquartile range, 2.7-11.7) years after transplantation. Multivariate Cox regression models were built, adjusting for measures of renal function and mineral metabolism; Framingham risk factors; the left ventricular wall strain markers midregional fragment of pro-A-type natriuretic peptide (MR-proANP) and N-terminal-pro brain natriuretic peptide (NT-proBNP); and copeptin, the stable C-terminal portion of the precursor of vasopressin. RESULTS: In multivariate linear regression analysis, MR-proANP (β=0.20, P<0.001), NT-proBNP (β=0.18, P<0.001), and copeptin (β=0.26, P<0.001) were independently associated with FGF23. During follow-up for 7.0 (interquartile range, 6.2-7.5) years, 128 patients (22%) died, of whom 66 (11%) died due to cardiovascular disease; 54 (9%) had graft failure. FGF23 was associated with an higher risk of cardiovascular mortality in a fully adjusted multivariate Cox regression model (hazard ratio [HR], 1.88 [95% confidence interval (CI), 1.11 to 3.19]; P=0.02). FGF23 was also independently associated with all-cause mortality (full model HR, 1.86 [95% CI, 1.27 to 2.73]; P=0.001). Net reclassification improved for both cardiovascular mortality (HR, 0.07 [95% CI, 0.01 to 0.14]; P<0.05) and all-cause mortality (HR, 0.11 [95% CI, 0.05 to 0.18]; P<0.001). CONCLUSIONS: Plasma FGF23 is independently associated with cardiovascular and all-cause mortality after kidney transplantation. The association remained significant after adjustment for measures of mineral metabolism and cardiovascular risk factors.
Authors: Victoria Shalhoub; Edward M Shatzen; Sabrina C Ward; James Davis; Jennitte Stevens; Vivian Bi; Lisa Renshaw; Nessa Hawkins; Wei Wang; Ching Chen; Mei-Mei Tsai; Russell C Cattley; Thomas J Wronski; Xuechen Xia; Xiaodong Li; Charles Henley; Michael Eschenberg; William G Richards Journal: J Clin Invest Date: 2012-06-25 Impact factor: 14.808
Authors: Johan Ärnlöv; Axel C Carlsson; Johan Sundström; Erik Ingelsson; Anders Larsson; Lars Lind; Tobias E Larsson Journal: Clin J Am Soc Nephrol Date: 2013-01-18 Impact factor: 8.237
Authors: Orlando M Gutiérrez; Michael Mannstadt; Tamara Isakova; Jose Alejandro Rauh-Hain; Hector Tamez; Anand Shah; Kelsey Smith; Hang Lee; Ravi Thadhani; Harald Jüppner; Myles Wolf Journal: N Engl J Med Date: 2008-08-07 Impact factor: 91.245
Authors: Aiko P J de Vries; Stephan J L Bakker; Willem J van Son; Jaap J Homan van der Heide; Rutger J Ploeg; Hauw T The; Paul E de Jong; Reinold O B Gans Journal: Am J Transplant Date: 2004-10 Impact factor: 8.086
Authors: Johan Ärnlöv; Axel C Carlsson; Johan Sundström; Erik Ingelsson; Anders Larsson; Lars Lind; Tobias E Larsson Journal: Kidney Int Date: 2012-09-05 Impact factor: 10.612
Authors: Marc G Vervloet; Arjan D van Zuilen; Annemieke C Heijboer; Piet M ter Wee; Michiel L Bots; Peter J Blankestijn; Jack F M Wetzels Journal: BMC Nephrol Date: 2012-04-24 Impact factor: 2.388
Authors: Michele F Eisenga; Marco van Londen; David E Leaf; Ilja M Nolte; Gerjan Navis; Stephan J L Bakker; Martin H de Borst; Carlo A J M Gaillard Journal: J Am Soc Nephrol Date: 2017-08-03 Impact factor: 10.121
Authors: Daniel Edmonston; Daniel Wojdyla; Rupal Mehta; Xuan Cai; Claudia Lora; Debbie Cohen; Raymond R Townsend; Jiang He; Alan S Go; John Kusek; Matthew R Weir; Tamara Isakova; Michael Pencina; Myles Wolf Journal: Am J Kidney Dis Date: 2019-08-21 Impact factor: 8.860
Authors: Charlotte A Keyzer; Martin H de Borst; Else van den Berg; Willi Jahnen-Dechent; Spyridon Arampatzis; Stefan Farese; Ivo P Bergmann; Jürgen Floege; Gerjan Navis; Stephan J L Bakker; Harry van Goor; Ute Eisenberger; Andreas Pasch Journal: J Am Soc Nephrol Date: 2015-04-29 Impact factor: 10.121
Authors: Amarnath Marthi; Killian Donovan; Richard Haynes; David C Wheeler; Colin Baigent; Christopher M Rooney; Martin J Landray; Sharon M Moe; Jun Yang; Lisa Holland; Romina di Giuseppe; Annet Bouma-de Krijger; Borislava Mihaylova; William G Herrington Journal: J Am Soc Nephrol Date: 2018-05-15 Impact factor: 10.121